COUNTERPOINT: INTERLEUKIN-6 DOES NOT HAVE A BENEFICIAL ROLE IN INSULIN SENSITIVITY AND GLUCOSE HOMEOSTASIS
2007; American Physiological Society; Volume: 102; Issue: 2 Linguagem: Inglês
10.1152/japplphysiol.01208a.2006
ISSN8750-7587
Autores Tópico(s)Adipose Tissue and Metabolism
ResumoPOINT-COUNTERPOINTCOUNTERPOINT: INTERLEUKIN-6 DOES NOT HAVE A BENEFICIAL ROLE IN INSULIN SENSITIVITY AND GLUCOSE HOMEOSTASISRobert A. MooneyRobert A. MooneyPublished Online:01 Feb 2007https://doi.org/10.1152/japplphysiol.01208a.2006MoreSectionsPDF (52 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookTwitterLinkedInWeChat Interleukin (IL)-6 is a pleiotropic cytokine with involvement in such diverse physiological and pathological functions as innate immunity and acute phase response, hematopoiesis, liver regeneration, and repair (1, 26). Evidence also supports a role for IL-6 in glucose metabolism and insulin action, but the nature of this role is controversial. As discussed by Dr. Pedersen and Dr. Febbraio, my Point:Counterpoint colleagues whose research has made major contributions to this field, IL-6 can display beneficial effects in regulating glucose metabolism, particularly in skeletal muscle (8). The important question as I see it, however, is whether IL-6, in pathological conditions, contributes to glucose dysregulation. Although IL-6 may have a benign or beneficial role under certain experimental conditions, I will argue that in its relationship to obesity and insulin resistance, which affects as many as one-third of adults in the United States, the contribution of IL-6 is decidedly detrimental, particularly in the liver.Recent evidence indicates that obesity, with its associated insulin resistance and Type 2 diabetes, is a chronic inflammatory state (29). Considerable effort is directed at determining the contribution of the cytokines, adipokines, and related factors to the altered glucose homeostasis and insulin resistance of this inflammatory state. Circulating IL-6 levels are two- to fourfold higher in obese, Type 2 diabetics than in nonobese controls (7, 17, 18). Kern et. al (12) reported that plasma IL-6 levels correlate better than TNF-α with obesity and insulin resistance. Similarly, Bastard et al. (3) reported that adipose tissue IL-6 levels but not TNF-α or leptin levels correlate with insulin resistance in obese subjects. IL-6 levels in serum and adipose tissue also decrease with weight loss (2). A recent study demonstrated that levels of CRP and IL-6 correlate with both insulin resistance and obesity and predict the development of Type 2 diabetes (19). Adipose tissue makes an important contribution to circulating IL-6 levels (16), and the liver is a well- characterized target of IL-6. Omental fat is more strongly linked to insulin resistance than non-visceral fat depots (6) and secretes as much as two- to threefold more IL-6 than subcutaneous fat (9). Importantly, venous drainage of omental fat uses the portal venous system, hence potentially having a preferential effect on the liver.Is IL-6 an active participant in the insulin resistance and altered carbohydrate metabolism of obesity or is this guilt by association? Both in vivo and in vitro evidence is available to address this question. Kanemaki et al. (11) and others (20) reported that IL-6 inhibits insulin-dependent glycogen synthesis and promotes glucose release from isolated primary hepatocytes. Our group has shown that IL-6 impairs insulin receptor signaling in HepG2 cells and primary hepatocytes and confirms that insulin-dependent glycogen synthesis is inhibited by IL-6 (23). Rotter et al. (21) reported that gene transcription of IRS-1, GLUT4, and PPAR-γ decreased in response to chronic IL-6 in 3T3L1 adipocytes. Insulin-dependent glucose transport and IRS-1 tyrosine phosphorylation were also suppressed.While in vitro investigations have shown direct inhibitory effects of IL-6 on insulin- responsive target cells, in vivo experiments also support such an effect of IL- 6. In rodents, IL-6 injections lead to increased plasma glucose and insulin levels after 90 min and a marked decrease in liver glycogen (25). Additionally, we reported that mice acutely exposed to IL-6 for 90 min have reduced insulin signal transduction in the liver (24). If the objective is to characterize the role of IL-6 in obesity, however, IL-6 levels should be maintained in a chronically elevated state to mimic obesity. To this end, we used implantable osmotic pumps that deliver IL-6 continuously to mice over 5–7 days. Under these conditions, IL-6 produced a hepatic insulin resistance as determined by impaired insulin receptor signal transduction. Interestingly, skeletal muscle response to insulin was unimpaired (15). Using a more acute IL-6 treatment, Kim et al. (13) infused IL-6 for 3 h during a hyperinsulinemic-euglycemic clamp study. Under these conditions, insulin resistance was observed in both the liver and skeletal muscle. Perhaps the latter reflects the higher dose used and the shorter time frame of the study.To directly address the role of IL-6 in glucose dysregulation of obesity, an IL-6 neutralizing antibody was used to deplete IL-6 in genetically obese Lepob mice (14). Prior to antibody treatment, elevated STAT3 phosphorylation and increased expression of acute phase proteins haptoglobin and fibrinogen were observed in liver and adipose tissue of the obese mice compared with lean controls, consistent with an obesity-associated elevation of endogenous IL-6. Neutralization of IL-6 returned these markers toward levels seen in lean mice. Importantly, insulin receptor signaling increased in the liver but not in adipose tissue in response to IL-6 depletion. Of relevance to our current discussion, depletion of IL-6 increased insulin sensitivity in the obese mice as reflected in a marked improvement in insulin-dependent suppression of endogenous glucose production (14). Cai et al. (4) reported a similar increase in hepatic insulin sensitivity following treatment of a transgenic mouse model of insulin resistance with IL-6 neutralizing antibody. They argue further that the liver can be an important source of IL-6, with steatosis being a potent stimulus for increased production.Is IL-6 a promoter of insulin sensitivity and glucose utilization as suggested in part by the expertly performed, acute, human studies by Drs. Pedersen, Febbraio, and colleagues, or is IL-6 the antagonist of insulin action as argued in the studies outlined here? What factors may account for the apparent contradictory effects of IL-6 on glucose homeostasis? Chronicity may be one factor. Most human investigations are by necessity limited to several hours. Obesity is a chronic condition, and the role of IL-6 in this condition may require chronic elevations. Chronic, but not acute, exposure to IL-6 causes inhibitory changes in insulin action in 3T3L1 adipocytes (21). Evidence from the liver regeneration field suggests that short-term (1–2 days) IL-6 exposure yields a protective effect, whereas long term (5–7 days) IL-6 exposure is injurious (10). Differences in response to IL-6 between the insulin responsive tissues are also a factor. While skeletal muscle appears to be the major target for the reported beneficial effects of IL-6, Weigert et al. (28) recently confirmed that, in the liver of mice, IL-6 activates two inhibitory mechanisms that are implicated in insulin resistance, marked induction of SOCS-3 and phosphorylation of IRS-1 on serine-307. Interestingly, IL-6 had no appreciable effect on these inhibitory mechanisms in skeletal muscle. Carey et al. (5) recently confirmed the small effect of IL-6 on SOCS-3 expression in muscle. This tissue-specific difference in induction of SOCS-3 may be quite relevant to this current discussion because we and others have linked SOCS-3 to inhibition of insulin receptor signal transduction in the liver (22, 24, 27). Finally, physiological context may play an important role in determining the response to an inflammatory cytokine such as IL-6. In 3T3L1 adipocytes, IL-6 alone had no acute effect and IL-1α had only a small inhibitory effect on insulin receptor signal transduction (28). Together, however, these two inflammatory cytokines very potently inhibited insulin receptor signaling. Thus, although considerable evidence supports a role for IL-6 in promoting insulin resistance and glucose dysregulation, optimum characterization of this role may require consideration of the synergy between IL-6 and other elements of the proinflammatory milieu.GRANTSThe author recognizes support from the National Institute of Diabetes and Digestive and Kidney Diseases (Grants DK-38138 and DK-60732) and the American Diabetes Association (7–04-RA-78).REFERENCES1 Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 54: 1–78, 1993.Crossref | PubMed | ISI | Google Scholar2 Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 85: 3338–3342, 2000.PubMed | ISI | Google Scholar3 Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J, Hainque B. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87: 2084–2089, 2002.Crossref | PubMed | ISI | Google Scholar4 Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11: 183–190, 2005.Crossref | PubMed | ISI | Google Scholar5 Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, Prelovsek O, Hohnen-Behrens C, Watt MJ, James DE, Kemp BE, Pedersen BK, Febbraio MA. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55: 2688–2697, 2006.Crossref | PubMed | ISI | Google Scholar6 Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 45: 633–638, 1996.Crossref | PubMed | ISI | Google Scholar7 Desfaits AC, Serri O, Renier G. Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment. Diabetes Care 21: 487–493, 1998.Crossref | PubMed | ISI | Google Scholar8 Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, Pedersen BK. Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 53: 1643–1648, 2004.Crossref | PubMed | ISI | Google Scholar9 Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83: 847–850, 1998.PubMed | ISI | Google Scholar10 Jin X, Zimmers TA, Perez EA, Pierce RH, Zhang Z, Koniaris LG. Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair. Hepatology 43: 474–484, 2006.Crossref | PubMed | ISI | Google Scholar11 Kanemaki T, Kitade H, Kaibori M, Sakitani K, Hiramatsu Y, Kamiyama Y, Ito S, Okumura T. Interleukin 1beta and interleukin 6, but not tumor necrosis factor alpha, inhibit insulin-stimulated glycogen synthesis in rat hepatocytes. Hepatology 27: 1296–1303, 1998.Crossref | PubMed | ISI | Google Scholar12 Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280: E745–E751, 2001.Link | ISI | Google Scholar13 Kim HJ, Higashimori T, Park SY, Choi H, Dong J, Kim YJ, Noh HL, Cho YR, Cline G, Kim YB, Kim JK. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53: 1060–1067, 2004.Crossref | PubMed | ISI | Google Scholar14 Klover PJ, Clementi AH, Mooney RA. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 146: 3417–3427, 2005.Crossref | PubMed | ISI | Google Scholar15 Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52: 2784–2789, 2003.Crossref | PubMed | ISI | Google Scholar16 Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82: 4196–4200, 1997.PubMed | ISI | Google Scholar17 Muller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B, Giani G, Illig T, Thorand B, Kolb H. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 45: 805–812, 2002.Crossref | PubMed | ISI | Google Scholar18 Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci 67: 291–300, 2000.Crossref | PubMed | ISI | Google Scholar19 Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286: 327–334, 2001.Crossref | PubMed | ISI | Google Scholar20 Ritchie DG. Interleukin 6 stimulates hepatic glucose release from prelabeled glycogen pools. Am J Physiol Endocrinol Metab 258: E57–E64, 1990.Link | Google Scholar21 Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3–L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278: 45777–45784, 2003.Crossref | PubMed | ISI | Google Scholar22 Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 277: 42394–42398, 2002.Crossref | PubMed | ISI | Google Scholar23 Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51: 3391–3399, 2002.Crossref | PubMed | ISI | Google Scholar24 Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, Mooney RA. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 278: 13740–13746, 2003.Crossref | PubMed | ISI | Google Scholar25 Stith RD, Luo J. Endocrine and carbohydrate responses to interleukin-6 in vivo. Circ Shock 44: 210–215, 1994.PubMed | Google Scholar26 Streetz KL, Luedde T, Manns MP, Trautwein C. Interleukin 6 and liver regeneration. Gut 47: 309–312, 2000.Crossref | PubMed | ISI | Google Scholar27 Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24: 5434–5446, 2004.Crossref | PubMed | ISI | Google Scholar28 Weigert C, Hennige AM, Lehmann R, Brodbeck K, Baumgartner F, Schauble M, Haring HU, Schleicher ED. Direct cross-talk of interleukin-6 and insulin signal transduction via insulin receptor substrate-1 in skeletal muscle cells. J Biol Chem 281: 7060–7067, 2006.Crossref | PubMed | ISI | Google Scholar29 Wellen KE, Hotamisligil GS. Inflammation, stress, diabetes. J Clin Invest 115: 1111–1119, 2005.Crossref | PubMed | ISI | Google Scholar Download PDF Previous Back to Top Next FiguresReferencesRelatedInformation Cited ByProspects of potential adipokines as therapeutic agents in obesity-linked atherogenic dyslipidemia and insulin resistance4 April 2023 | The Egyptian Heart Journal, Vol. 75, No. 1Exercise as a Moderator of Persistent Neuroendocrine Symptoms of COVID-1912 January 2022 | Exercise and Sport Sciences Reviews, Vol. 50, No. 2Carbohydrate and Protein Supplements, an Effective Means for Maintaining Exercise-Induced Glucose Metabolism HomeostasisJournal of Biomaterials and Tissue Engineering, Vol. 11, No. 6Clinical Impact of Insulin Resistance in Women with Polycystic Ovary Syndrome15 April 2020Circulatory levels of pro-inflammatory cytokines (IL-6 and IL-1β) and neutrophil-lymphocyte ratio (NLR) in diabetic patients in Nigerian population30 January 2020 | Comparative Clinical Pathology, Vol. 29, No. 2Targeting innate immune mediators in type 1 and type 2 diabetes9 September 2019 | Nature Reviews Immunology, Vol. 19, No. 12Interleukin-6 increases the expression and activity of insulin-degrading enzyme21 April 2017 | Scientific Reports, Vol. 7, No. 1An ALPHA7 Nicotinic Acetylcholine Receptor Agonist (GTS-21) Promotes C2C12 Myonuclear Accretion in Association with Release of Interleukin-6 (IL-6) and Improves Survival in Burned MiceShock, Vol. 48, No. 2Circulating Soluble IL-6 Receptor Concentration and Visceral Adipocyte Size Are Related to Insulin Resistance in Taiwanese Adults with Morbid ObesityMetabolic Syndrome and Related Disorders, Vol. 15, No. 4Maraviroc Ameliorates the Increased Adipose Tissue Macrophage Recruitment Induced by a High-Fat Diet in a Mouse Model of Obesity1 February 2016 | Antiviral Therapy, Vol. 22, No. 2White Adipose Tissue4 April 2017Metabolic Syndrome in Rheumatoid Arthritis17 September 2015Loss of Ron receptor signaling leads to reduced obesity, diabetic phenotypes and hepatic steatosis in response to high-fat diet in miceWilliam D. Stuart, Nicholas E. Brown, Andrew M. Paluch, and Susan E. Waltz1 April 2015 | American Journal of Physiology-Endocrinology and Metabolism, Vol. 308, No. 7Muscle-specific interleukin-6 deletion influences body weight and body fat in a sex-dependent mannerBrain, Behavior, and Immunity, Vol. 40Interleukin‐6 deletion in mice driven by a P 2‐ C re‐ ERT 2 prevents against high‐fat diet‐induced gain weight and adiposity in female mice1 July 2014 | Acta Physiologica, Vol. 211, No. 4Role of interleukins in obesity: implications for metabolic diseaseTrends in Endocrinology & Metabolism, Vol. 25, No. 6Targeting inflammation in the treatment of type 2 diabetes: time to start23 May 2014 | Nature Reviews Drug Discovery, Vol. 13, No. 6Gastric Bypass and Sleeve Gastrectomy: the Same Impact on IL-6 and TNF-α. Prospective Clinical Trial10 March 2013 | Obesity Surgery, Vol. 23, No. 8Inflammation in Obesity and Diabetes: Islet Dysfunction and Therapeutic OpportunityCell Metabolism, Vol. 17, No. 6Modulation of hsa-miR-26b levels following adipokine stimulation30 December 2012 | Molecular Biology Reports, Vol. 40, No. 5Paradoxical Glucose-Sensitizing yet Proinflammatory Effects of Acute ASP Administration in MiceMediators of Inflammation, Vol. 2013Interleukin‐6 mediates exercise‐induced increase in insulin sensitivity in mice31 May 2012 | Experimental Physiology, Vol. 97, No. 11Effects of blackcurrant-based juice on atherosclerosis-related biomarkers in cultured macrophages and in human subjects after consumption of a high-energy meal20 October 2011 | British Journal of Nutrition, Vol. 108, No. 2Plasticity and cross-talk of Interleukin 6-type cytokinesCytokine & Growth Factor Reviews, Vol. 23, No. 3Interleukin-1 Receptor Antagonist: A New Therapy for Type 2 Diabetes MellitusJournal of Pharmaceutical Sciences, Vol. 101, No. 5Role of cardiotrophin-1 in obesity and insulin resistance20 October 2014 | Adipocyte, Vol. 1, No. 2PGRN is a Key Adipokine Mediating High Fat Diet-Induced Insulin Resistance and Obesity through IL-6 in Adipose TissueCell Metabolism, Vol. 15, No. 1IL-6 Muscles In on the Gut and Pancreas to Enhance Insulin SecretionCell Metabolism, Vol. 15, No. 1Periodontitis and Insulin Resistance: Casual or Causal Relationship?Diabetes & Metabolism Journal, Vol. 36, No. 6White Adipose Tissue15 October 2011Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells30 October 2011 | Nature Medicine, Vol. 17, No. 11Adipokines in inflammation and metabolic disease21 January 2011 | Nature Reviews Immunology, Vol. 11, No. 2Type 2 diabetes as an inflammatory disease14 January 2011 | Nature Reviews Immunology, Vol. 11, No. 2The effects of acylation stimulating protein supplementation VS antibody neutralization on energy expenditure in wildtype mice23 April 2010 | BMC Physiology, Vol. 10, No. 1cJun NH2-terminal kinase 1 (JNK1): roles in metabolic regulation of insulin resistanceTrends in Biochemical Sciences, Vol. 35, No. 9Gender-specific associations between insulin resistance, hypertension, and markers of inflammation among adult Saudis with and without diabetes mellitus type 2Advances in Medical Sciences, Vol. 55, No. 2Transgenic mice with astrocyte-targeted production of interleukin-6 are resistant to high-fat diet-induced increases in body weight and body fatBrain, Behavior, and Immunity, Vol. 24, No. 1Pancreatic islet inflammation in type 2 diabetes: From α and β cell compensation to dysfunction3 August 2009 | Archives of Physiology and Biochemistry, Vol. 115, No. 4Getting the message across: mechanisms of physiological cross talk by adipose tissueDo-Eun Lee, Sylvia Kehlenbrink, Hanna Lee, Meredith Hawkins, and John S. Yudkin1 June 2009 | American Journal of Physiology-Endocrinology and Metabolism, Vol. 296, No. 6The role of interleukins in insulin resistance and type 2 diabetes mellitus28 April 2009 | Nature Reviews Endocrinology, Vol. 5, No. 6A Stress Signaling Pathway in Adipose Tissue Regulates Hepatic Insulin ResistanceScience, Vol. 322, No. 5907Hypothalamic Control of Hepatic Glucose Production and Its Potential Role in Insulin ResistanceEndocrinology and Metabolism Clinics of North America, Vol. 37, No. 4Adipokines and Insulin Resistance1 November 2008 | Molecular Medicine, Vol. 14, No. 11-12Muscle as an Endocrine Organ: Focus on Muscle-Derived Interleukin-6Bente K. Pedersen and Mark A. Febbraio1 October 2008 | Physiological Reviews, Vol. 88, No. 4Interleukin-6 regulates pancreatic α-cell mass expansion2 September 2008 | Proceedings of the National Academy of Sciences, Vol. 105, No. 35Inflammation‐associated insulin resistance: Differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms24 June 2008 | Arthritis & Rheumatism, Vol. 58, No. 7Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen speciesYongzhong Wei, Kemin Chen, Adam T. Whaley-Connell, Craig S. Stump, Jamal A. Ibdah, and James R. Sowers1 March 2008 | American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, Vol. 294, No. 3The role of interleukin‐6 in insulin resistance, body fat distribution and energy balance23 October 2007 | Obesity Reviews, Vol. 9, No. 1 More from this issue > Volume 102Issue 2February 2007Pages 816-818 Copyright & PermissionsCopyright © 2007 the American Physiological Societyhttps://doi.org/10.1152/japplphysiol.01208a.2006PubMed17284655History Published online 1 February 2007 Published in print 1 February 2007 Metrics
Referência(s)